About Gregor Diagnostics
Gregor Diagnostics is a company based in Madison (United States) founded in 2016. Gregor Diagnostics has raised $10.49 million across 8 funding rounds from investors including Gener8tor, First Round Capital and Green Park & Golf Ventures. Gregor Diagnostics offers products and services including Reflex 1+ Genomic classifier, Reflex 2+ Genomic classifier, and Active Surveillance Genomic classifier. Gregor Diagnostics operates in a competitive market with competitors including Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and BillionToOne, among others.
- Headquarter Madison, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gregor Diagnostics Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.49 M (USD)
in 8 rounds
-
Latest Funding Round
$242.03 K (USD), Series A
Oct 20, 2025
-
Investors
Gener8tor
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gregor Diagnostics
Gregor Diagnostics offers a comprehensive portfolio of products and services, including Reflex 1+ Genomic classifier, Reflex 2+ Genomic classifier, and Active Surveillance Genomic classifier.
Detects prostate cancer before biopsy to prevent overdiagnosis.
Distinguishes benign from serious cancers for treatment decisions.
Monitors prostate cancer in patients on active surveillance programs.
People of Gregor Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of Gregor Diagnostics
Gregor Diagnostics has successfully raised a total of $10.49M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $242.03 thousand completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gregor Diagnostics
Gregor Diagnostics has secured backing from 7 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Gener8tor, First Round Capital and Green Park & Golf Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused seed and early-stage VC firm
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are made in medical startups.
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated via a 12-week funding program.
|
Locked | Locked | Locked |
Investor details for Gregor Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gregor Diagnostics
Investment portfolio details for Gregor Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gregor Diagnostics
Detailed financials for Gregor Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gregor Diagnostics Comparisons
Peer comparison for Gregor Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gregor Diagnostics
Gregor Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and BillionToOne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Non-invasive blood tests for prenatal fetal health predictions are offered.
|
Detailed competitors of Gregor Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gregor Diagnostics
Complete news archive for Gregor Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gregor Diagnostics
Gregor Diagnostics was founded in 2016.
Gregor Diagnostics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Steven Weinstein is the current CEO of Gregor Diagnostics.
Gregor Diagnostics is a funded company, having raised a total of $10.49M across 8 funding rounds to date.
Gregor Diagnostics was founded in 2016 in Madison, United States, within the healthcare diagnostics sector. A proprietary assay is utilized to analyze seminal fluid for eight cancer-associated biomarkers, which may not be detected in blood or urine tests. Patients are stratified into categories of no cancer, indolent cancer, or aggressive cancer. At-home sample collection kits are sent to the company for processing and results.
Gregor Diagnostics's top competitors include Guardant Health, GRAIL and BillionToOne.
Gregor Diagnostics offers Reflex 1+ Genomic classifier, Reflex 2+ Genomic classifier, and Active Surveillance Genomic classifier.
Gregor Diagnostics has 7 investors. Key investors include Gener8tor, First Round Capital, Green Park & Golf Ventures, Nat Turner, and Zach Weinberg.